NEW YORK (GenomeWeb) – Shanghai Biotechnology, a Chinese biomarker discovery firm, and Akesogen, a Norcross, Ga.-based genomic contract resources organization, announced yesterday they will form a strategic business development alliance that will enable the firms to work on joint projects with pharmaceutical and biotechnology clients in the US and Asia.
The partnership brings together Akesogen´s experience in sequencing, genotyping, methylation profiling, expression profiling, PCR, qPCR, copy number variation, and DNA and RNA extractions with Shanghai Biotech's expertise in comprehensive genomic and pharmacogenomic services, the firms said in a statement.
"Shanghai Biotechnology Corporation's services are very complimentary to Akesogen's. This partnership will allow us to jointly develop important opportunities that span the Asian and US genomics markets" Akesogen CEO Bob Boisjoli said in a statement.
In May 2014, Akesogen signed a similar international partnership with Kassel, Germany-based clinical biomarker services firm Targos Molecular Pathology.
Financial and other details of the agreement were not disclosed.